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Tuberculosis (TB) is an infectious disease caused by members of Mycobacterium tubercu-
losis complex. Despite the availability of effective treatments, TB remains a major public
health concern in most low and middle-income countries, representing worldwide the
second leading cause of death from an infectious disease. Inadequate case detection and
failures to classify the disease status hamper proper TB control. The limitations of the
conventional diagnostic methods have encouraged much research activities in this ﬁeld,
but there is still an urgent need for an accurate point of care test for active TB diagnosis.
A rapid, precise, and inexpensiveTB diagnostic test would allow an earlier implementation
of an appropriate treatment and the reduction of disease transmission. Pathogen-derived
molecules present in clinical specimens of affected patients are being validated for that
purpose. This short review aims to summarize the available data regarding biomarkers
derived from M. tuberculosis, and their current usage in active TB diagnosis.
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INTRODUCTION
Tuberculosis (TB) is a major global health problem and one
of the most important causes of death from an infectious dis-
ease. In 2012, 8.6 million people developed TB and 1.3 million
died from the disease (WHO, 2013). Despite substantial invest-
ments and progress made in the implementation of Stop TB
strategy by the World Health Organization (WHO), inadequate
case detection and failures to accurately classify the disease sta-
tus still hamper the control of TB (Wallis et al., 2010a; McNerney
et al., 2012). Most humans infected with Mycobacterium tubercu-
losis (MTB) remain asymptomatic, and only a small proportion
develops active TB disease. Typically the bacterium establishes a
latent infection and the lifetime risk of developing the disease is
near 10% unless an individual becomes immunocompromised, at
which time the risk increases signiﬁcantly (Young et al., 2008). TB
is usually a chronic, slowly progressing disease that often keeps
undiagnosed in patients for many years. In adults the most com-
mon form is chronic pulmonary TB, while extrapulmonary TB is
especially common in children and HIV-coinfected patients (Jain,
2011).
The diagnosis of active TB is critical for controlling the dis-
ease. Conventional diagnostic methods of active TB include
sputum smear microscopy (pulmonary TB) and M. tuberculosis
isolation in bacteriological culture (currently the gold standard
for deﬁnitive diagnosis of pulmonary and extrapulmonary TB).
Although these methods are widely used for diagnosing TB,
they suffer of speciﬁcity and sensitivity limitations (Tiwari et al.,
2007; WHO, 2013), and microbiological culture takes several
weeks to conﬁrm a clinical diagnosis. Besides, both meth-
ods require highly skilled personnel and specialized laboratory
infrastructure.
Recently, PCR based diagnostic methods were launched. The
GeneXpert MTB/RIF (Cepheid Inc., USA) is a cartridge-based,
automatic nucleic acid ampliﬁcation test, for TB case detection
and rifampicin resistance testing. It puriﬁes, ampliﬁes, and iden-
tiﬁes targeted nucleic acid sequences in the TB genome, and
provides results from unprocessed sputum samples in less than
2 h (Boehme et al., 2010). This assay showed a high sensitivity in
both pulmonary (Boehme et al., 2010) and extrapulmonary TB
(Hillemann et al., 2011). It was endorsed by WHO (2011a) for use
in TB endemic countries. However, its high cost is a main bar-
rier for the popularization of this new technology out of reference
laboratories, in areas where the prevalence of the disease is higher
(Steingart et al., 2012).
Unlike many other infectious diseases, in TB the speciﬁc anti-
body response is not so well understood. That is a consequence
of the complex and highly evolved relationship of the pathogen
with the immune system, its intracellular localization, and our
partial understanding of its biology and host–pathogen interac-
tion. This fact has largely frustrated the attempts to exploit the
host response in antibody detection diagnostic assays, which could
constitute an economical diagnostic alternative in low income
countries (Young et al., 2008). A systematic review of the perfor-
mance of various commercial serological tests has evidenced that
this approach does not allow a reliable diagnosis of TB, reporting
inconsistent, imprecise, and highly variable values for sensitivity
and speciﬁcity (Steingart et al., 2011). Considering that situation
in 2011, WHO issued a policy recommending not using these tests
for the diagnosis of pulmonary and extra-pulmonary TB (WHO,
2011b).
In this context, a major focus of the WHO’s global plan to
stop TB is the development of a simple and cost-effective diag-
nostic method to improve case detection (Pollock et al., 2013).
Until the moment TB lacks an accurate rapid point-of-care (POC)
diagnostic test that could distinguish individuals with active TB
from those with latent disease or not infected (McNerney et al.,
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2012; Pollock et al., 2013). The failure of diagnostic tests based
on the antibody response has greatly stimulated the interest in
the development of rapid antigen detection methods (WHO,
2009). For that purpose much work is being performed aiming
to discover and validate robust host and pathogen biomarkers
of M. tuberculosis infection and disease (Doherty et al., 2009).
This minireview covers M. tuberculosis-derived molecules iden-
tiﬁed in clinical samples of infected patients, and thus, could be
proposed as diagnostic markers candidates. Bearing a potential
correlation with the actual load of bacteria, they can be used both
for diagnosis and treatment monitoring (WHO, 2009). Among
these molecules, this review focuses on antigenic compounds that
can be detected with antibodies in antigen detection assays, being
particularly attractive for the development of POC diagnostic test.
Other pathogen-derived markers [DNA,RNA, and molecules with
enzymatic activities (Xie et al., 2012)] are out of the scope of this
review.
PATHOGEN-DERIVED BIOMARKERS
A biomarker is deﬁned as a parameter that can be objectively mea-
sured as an indicator of normal or pathogenic biological processes,
or as an indicator of pharmacological responses to therapeu-
tic interventions (Wallis et al., 2010a,b; McNerney et al., 2012).
In routine clinical care, biomarkers allow stratiﬁcation of indi-
vidual patients, thus helping to develop targeted interventions
that might not otherwise produce overall beneﬁts (Wallis et al.,
2010a).
In an infectious disease biomarkers can be either host or
pathogen-derived (McNerney et al., 2012). Human immunodeﬁ-
ciency virus (HIV) infection offers a prime example of biomarker’s
utility both for initial diagnosis and for the evaluation of disease
state and progression. After HIV infection, viral RNA, and p24
antigen detection are used to establish an early diagnosis. After-
ward, to evaluate HIV progression, viral load is measured by viral
RNA quantiﬁcation, and disease evolution is evaluated through
CD4+ cell counts (Constantine and Zink, 2005). In that case
understanding of the pathogen dynamics and kinetics of the host
immune response during the disease allowed the development of
accurate diagnostic tests.
A main challenge in TB is to identify and validate consistent
markers which could be translated into a speciﬁc and sensitive
diagnostic test. Unfortunately, knowledge in that ﬁeld is still par-
tial, and requires a better understanding of the disease and the
host-pathogen interaction (Young et al., 2008). It is expected that
the identiﬁcation of speciﬁc molecular markers would help to
the development of an in vitro diagnostic test for M. tuberculo-
sis active infection, which should be rapid, inexpensive, sensitive,
and appropriate to be used in peripheral laboratories with low
level of infrastructure.
PRINCIPAL M. tuberculosis DERIVED BIOMARKERS
To be considered as targets for antigen detection assays, pathogen-
derived molecules must reach the sample matrixes (sputum, urine,
plasma, etc.) in detectable levels (Bekmurzayeva et al., 2013). To be
valuable as diagnostic biomarkers these antigens should be specif-
ically and ubiquitously detected in clinical samples of infected
patients.
An antigen detection assay for TB could be performed using
a variety of clinical specimens such us sputum, blood, urine,
saliva, cerebrospinal ﬂuid (CSF), and pleural ﬂuid. Antigens that
are shed from M. tuberculosis in infected tissues can be present
in the body ﬂuids surrounding these tissues wherefrom they
can reach the blood circulation and be eliminated in urine, a
highly practical specimen for diagnostic tests. Urine is safer to
handle and less variable than sputum, besides it is easier to col-
lect from both adults and children. Additionally, urine based
assays could facilitate TB diagnosis in HIV co-infected patients,
who normally have a low bacterial load in sputum (WHO,
2009). Finally, in patients suspected of extrapulmonary TB, an
antigen detection test might prevent the use of more invasive
tests (WHO, 2009; Flores et al., 2011). These characteristics, if
paired with an appropriate and simple method for antigen detec-
tion, make this approach applicable at the community level of
the health system, so major efforts are being made to iden-
tify pathogen-derived antigens excreted in urine (Choudhry and
Saxena, 2002).
One of the most promising antigens that are being evaluated
is lipoarabinomannan (LAM). LAM is a structurally important
component of the outer cell wall of all bacteria of the genus
Mycobacterium that is shed from metabolically active or degrading
cells, is cleared by the kidney and detectable in urine (Hunter et al.,
1986; Chan et al., 1991). Antigen detection assays were described
for LAM, most of which are based on a sandwich capture ELISA
format to detect LAM in sputum (Pereira Arias-Bouda et al., 2000)
or urine (Hamasur et al., 2001; Boehme et al., 2005; Mutetwa et al.,
2009). As it will be described below, this antigen is being currently
evaluated by a lateral ﬂow test for rapid LAM detection in urine
(Minion et al., 2011).
In addition to LAM, deﬁned M. tuberculosis protein antigens
were assayed as target for antigen detection assays. The tested
proteins are generally major components that have been identiﬁed
by electrophoresis and mass spectrometry both in total extracts
and culture ﬁltrate of M. tuberculosis (Malen et al., 2007; Mattow
et al., 2003). Table 1 summarizes available information from these
antigens provided in TB Genomes Database (Reddy et al., 2009)
and TubercuList (Lew et al., 2011). It is important to mention that
many former published studies described the use of an antigen
based only upon its apparent molecular weight on SDS-PAGE and
without further identiﬁcation of the protein. This is the case of a
55 kDa antigen (Rv not reported) present in serum of pulmonary
(Attallah et al., 2003) and extra-pulmonary TB patients (Attallah
et al., 2005), and a 20 kDa antigen (Rv not reported) detected in
MTB crude extracts and serum of pulmonary TB patients (El-
Masry et al., 2008).
More recently, high throughput approaches were designed
to facilitate new biomarker discovery, based on proteomic
approaches employing clinical samples from active TB patients.
Thereby, four M. tuberculosis proteins were detected in urine
samples, which were identiﬁed as a possible molybdopterin
biosynthesis protein MoeX (Rv1681), a probable ornithine
carbamoyltransferase ArgF (Rv1656), a probable homoser-
ine O-acetyltransferase MetA (Rv3341) and a probable 3′-
phosphoadenosine 5′-phosphosulfate reductase CysH (Rv2392;
Kashino et al., 2008; Napolitano et al., 2008). These proteins
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constitute interesting candidates for the development of antigen
detection assays, and recently the gene coding for MoeX, unique to
the M. tuberculosis complex, was clinically validated as a diagnostic
biomarker for active pulmonary TB (Pollock et al., 2013).
DIAGNOSTIC PERFORMANCE AND COMMERCIAL
DEVELOPMENT
Asmall number of commercial prototypeTBdiagnostic tests based
on antigen detection have been developed, and some of them
were evaluated for clinical diagnostic performance. These tests
includes: Patho-TB (Anda Biologicals, France), Diagnos TB Ag
(Biomed Industries, India), LAM-ELISA (Chemogen, USA, a pro-
totype test not currently available),ClearviewTBELISA (Inverness
Medical Innovations, USA) and Determine TB-LAM (Alere Inc.,
USA; Flores et al., 2011; Minion et al., 2011). Two recent system-
atic reviews and meta-analysis highlighted that these tests showed
heterogeneous values of sensitivity and speciﬁcity through clinical
evaluations (Flores et al., 2011; Minion et al., 2011).
Some of these tests were designed to detect different M. tuber-
culosis antigens in sputum. Patho-TB rapid diagnostic test uses
polyclonal antibodies to detect mycobacterial antigens (including
65 and 85 kDa antigens) in sputum samples, previously decon-
taminated and imprinted in a ﬁlter cartridge. This test showed
a sensitivity ranging from 90 to 96% and speciﬁcity between
70 and 100% in different evaluation studies (Fabre et al., 2007;
Alavi-Naini et al., 2009; Ben-Selma et al., 2009). Another rapid
test designed to detect mycobacterial antigens in sputum [includ-
ing LAM and antigen 85B (Rv1886)] using polyclonal antibodies
is Diagnos TB Ag. The test comprises the inactivation and lysis
of the sputum sample, loading of the sample on a membrane
device and immune-detection of speciﬁc antigens. It showed a
variable performance in twopublished studies: a sensitivity of 98%
and speciﬁcity of 99% in TB infected HIV sero-positive patients
(Chakraborty et al., 2009) versus a 60% sensibility and 33% speci-
ﬁcity in HIV positive and TB negative infected patients (Reither
et al., 2010).
Another group of tests is based on LAM detection in urine.
Diagnostic tests based on the detection of LAM in urine were
among the ﬁrst to move from research to commercial stage,
due to their promising initial results (Hamasur et al., 2001;
Boehme et al., 2005). However, they have not yet been rou-
tinely applied in remote points of care settings (Minion et al.,
2011; Pai and Pai, 2012). The conﬂicting results obtained with
these tests can be explained, in part, by the lack of speci-
ﬁcity of the anti-LAM antibodies, since even anti-LAM mono-
clonal antibodies cross-react with most species of Mycobacterium,
including M. avium and M. leprae (Hunter et al., 1986; WHO,
2009).
The LAM-ELISA (Chemogen Inc., Portland, USA) was the
ﬁrst LAM targeting assayed prototype (Boehme et al., 2005; Daley
et al., 2009; Lawn et al., 2009; Mutetwa et al., 2009; Reither et al.,
2009). Afterward another commercial version named Clearview
TB ELISA (Alere Inc., USA – formerly Inverness Medical Innova-
tions, Inc.) was launched (Dheda et al., 2010; Shah et al., 2010).
Both tests use polyclonal anti-LAM antibodies in a capture sand-
wich ELISA format. A meta-analysis of published clinical studies
with different versions of these tests showed that 57% of urine
samples from smear positive TB patients were positive for LAM,
indicating that this test would not be sufﬁciently sensitive to
replace sputum microscopy. Nevertheless, 41% of smear negative
TB patients were positive for LAM, suggesting that LAM testing
and sputum microscopy used together could help diagnose differ-
ent groups of patients with TB (Minion et al., 2011). In addition,
it has been reported that a pre-analytical 100-fold-concentrating
step of urine samples increased signiﬁcantly the sensitivity of the
Clearview TB ELISA (Savolainen et al., 2013), yet the method still
needs to be reﬁned to become a viable tool for TB diagnosis.
Promisingly, a POC lateral ﬂow dipstick version of urinary
LAM detection (Determine TB LAM Ag, Alere Inc.) has been
developed. Following its commercial launch in 2013, Determine
TB-LAM remains the focus of ongoing clinical evaluation studies.
This is a simple, low-cost, POC assay which provides a qualitative
(yes/no) readout of TB diagnosis within 30 min (Lawn, 2014).
While diagnostic evaluation of this kit showed a poor perfor-
mance with unselected TB patients, combination of LAM lateral
ﬂow testwith sputummicroscopy demonstrated a diagnostic value
in HIV immunocompromised TB patients (CD4 lymphocyte cell
counts <50/μL; Lawn et al., 2012; Peter et al., 2012). These and
other studies largely conﬁrm that the sensitivity of Determine TB-
LAM is greatest (range 60–70%) among HIV-infected patients
with the most advanced immunodeﬁciency (Lawn et al., 2013).
HIV-associated pulmonary TB is of major concern in many coun-
tries of Africa, thus this kit could assist to establish a quicker
diagnosis and an earlier treatment in this high risk population. As
the evidence base grows, data on this assay would be reviewed by
an expert panel convened byWHO to deﬁne the role of the assay as
an add-on test within existing diagnostic algorithms (Lawn et al.,
2013).
CONCLUSION
A reliable POC diagnostic test for active TB detection is urgently
needed and much work is being done for that purpose. In the TB
diagnostic ﬁeld, antigendetection technologies andbiomarker dis-
covery strategies are rapidly evolving. While there are promising
evidences endorsing some of the commercially available diagnos-
tic tests, none of the new tools designed so far have shown an
outstanding diagnostic performance as to promote its widespread
application in medical practice. It is highly expected that in the
coming years more light is shed to aid in that goal.
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